Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Ruxolitinib in Patients With Myelofibrosis
- Conditions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 51
- Registration Number
- NCT05762874
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 20
- Registration Number
- NCT05762640
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05745714
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
- Conditions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05722912
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT05714072
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Yi-Lun Wang
- Target Recruit Count
- 6
- Registration Number
- NCT05663827
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taoyuan, Taiwan
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 56
- Registration Number
- NCT05622318
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 115
- Registration Number
- NCT05600855
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 40
- Registration Number
- NCT05599256
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Jonathan Brammer
- Target Recruit Count
- 28
- Registration Number
- NCT05592015
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.